PET Imaging of Hepatocellular Carcinoma Using ZD2-(

EDB fibronectin peptide ligand positron emission tomography woodchuck model

Journal

Journal of hepatocellular carcinoma
ISSN: 2253-5969
Titre abrégé: J Hepatocell Carcinoma
Pays: New Zealand
ID NLM: 101674775

Informations de publication

Date de publication:
2023
Historique:
received: 10 10 2022
accepted: 14 02 2023
entrez: 2 3 2023
pubmed: 3 3 2023
medline: 3 3 2023
Statut: epublish

Résumé

We tested a recently developed short peptide radioligand for PET imaging of hepatocellular carcinoma (HCC) by targeting an oncoprotein, extra-domain B fibronectin (EDB-FN) in the tumor microenvironment. The radioligand consists of a small linear peptide ZD2 with For ZD2 avid liver tumors, the radioligand accumulation plateaued a few minutes after injection, while the liver background uptake stabilized 20 min post-injection. The status of EDB-FN in woodchuck HCC was confirmed by histology and validated by PCR and western blocking. We have showed the viability of using the ZD2 short peptide radioligand targeting EDB-FN in liver tumor tissue for PET imaging of HCC, which can potentially impact the clinical care for HCC patients.

Identifiants

pubmed: 36860804
doi: 10.2147/JHC.S390939
pii: 390939
pmc: PMC9968869
doi:

Types de publication

Journal Article

Langues

eng

Pagination

291-301

Informations de copyright

© 2023 Sergeeva et al.

Déclaration de conflit d'intérêts

Dr Songqi Gao reports a patent WO2020150617A8 licensed to CWRU. Dr Zheng-Rong Lu reports a patent US Patent App. 17/424,104 pending to Molecular Theranostics, LLC. The authors report no other conflicts of interest in this work.

Références

Mol Imaging Biol. 2007 May-Jun;9(3):135-43
pubmed: 17308952
Clin Cancer Res. 2003 Feb;9(2):571-9
pubmed: 12576420
Cancer Res. 2015 Jun 1;75(11):2316-2325
pubmed: 25858145
Br J Radiol. 2012 Sep;85(1017):e573-83
pubmed: 22919011
Genome Biol. 2014;15(12):550
pubmed: 25516281
Mol Pharm. 2010 Dec 6;7(6):2077-92
pubmed: 20698576
J Cancer Res Clin Oncol. 2008 Oct;134(10):1059-65
pubmed: 18386055
Mol Imaging Biol. 2014 Feb;16(1):44-52
pubmed: 23921714
Comp Biochem Physiol C Toxicol Pharmacol. 2006 Jun;143(2):225-31
pubmed: 16581304
J Comput Chem. 2010 Jan 30;31(2):455-61
pubmed: 19499576
J Nucl Med. 2019 Mar;60(3):386-392
pubmed: 30072500
Hepatology. 1989 Mar;9(3):461-70
pubmed: 2465987
Q J Nucl Med Mol Imaging. 2009 Apr;53(2):144-56
pubmed: 19039303
Clin Cancer Res. 2008 Aug 1;14(15):4951-60
pubmed: 18676770
J Submicrosc Cytol Pathol. 1993 Apr;25(2):285-95
pubmed: 7686813
J Pathol. 1999 Jun;188(2):163-7
pubmed: 10398159
Oral Oncol. 2005 Jan;41(1):82-8
pubmed: 15598590
J Cell Biol. 2017 Nov 6;216(11):3799-3816
pubmed: 29021221
Cancer Detect Prev. 1989;14(2):227-9
pubmed: 2695243
Cancer Res. 1990 Mar 1;50(5):1608-12
pubmed: 2406016
ACS Omega. 2019 Jan 31;4(1):1185-1190
pubmed: 30729224
Mol Imaging Biol. 2011 Feb;13(1):140-51
pubmed: 20401538
Hepatogastroenterology. 2003 Nov-Dec;50(54):2154-6
pubmed: 14696485
Sci Rep. 2012;2:539
pubmed: 22844580
Hepatology. 2012 Sep;56(3):820-30
pubmed: 22431061
J Hepatol. 2017 Feb;66(2):355-362
pubmed: 27693539
Bioconjug Chem. 2017 Apr 19;28(4):1031-1040
pubmed: 28201871
J Nucl Med. 2009 May;50 Suppl 1:122S-50S
pubmed: 19403881
Br J Cancer. 2005 Sep 5;93(5):565-70
pubmed: 16091757
J Nucl Med. 2011 Jan;52(1):98-106
pubmed: 21149484
Cancer Res. 2000 Jan 1;60(1):164-9
pubmed: 10646869
HPB Surg. 2011;2011:789323
pubmed: 21941408
Front Oncol. 2019 Dec 03;9:1351
pubmed: 31850230
Eur J Nucl Med Mol Imaging. 2011 Jul;38(7):1248-56
pubmed: 21344223
Cancer Res. 2010 Jul 1;70(13):5238-48
pubmed: 20516121
Jpn J Cancer Res. 1999 Mar;90(3):320-5
pubmed: 10359047
Cancer Microenviron. 2014 Aug;7(1-2):33-9
pubmed: 24214412
Gastroenterology. 2004 Nov;127(5 Suppl 1):S283-93
pubmed: 15508096
J Biochem Biophys Methods. 2007 Jun 10;70(4):649-55
pubmed: 17399795
Am J Nucl Med Mol Imaging. 2019 Oct 15;9(5):216-229
pubmed: 31772820
Int J Cancer. 1994 Oct 1;59(1):11-6
pubmed: 7927891
J Cell Biol. 2017 Nov 6;216(11):3509-3520
pubmed: 28931556
Int J Cancer. 2006 Mar 15;118(6):1331-9
pubmed: 16381025
Cell Differ Dev. 1990 Dec 2;32(3):409-16
pubmed: 1711920
Cells. 2020 Aug 03;9(8):
pubmed: 32756405
J Nucl Med. 2019 Jun;60(6):801-805
pubmed: 30954939
Theranostics. 2020 Sep 8;10(24):11127-11143
pubmed: 33042274
Mol Imaging Biol. 2014 Aug;16(4):459-68
pubmed: 24488484
J Nucl Med. 2006 Oct;47(10):1707-16
pubmed: 17015908
Hepatology. 2005 Nov;42(5):1208-36
pubmed: 16250051
Blood. 2009 Mar 5;113(10):2265-74
pubmed: 19131554
Bioconjug Chem. 2015 May 20;26(5):830-8
pubmed: 25848940
Curr Cancer Drug Targets. 2014;14(4):407-17
pubmed: 24575976

Auteurs

Olga Sergeeva (O)

Department of Radiology, Case Western Reserve University, Cleveland, OH, USA.

Yifan Zhang (Y)

Department of Radiology, Case Western Reserve University, Cleveland, OH, USA.

Songqi Gao (S)

Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA.

E Ricky Chan (ER)

Cleveland Institute for Computational Biology, Case Western Reserve University, Cleveland, OH, USA.

Maxim Sergeev (M)

Department of Radiology, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.

Renuka Iyer (R)

Medical Oncology and Laboratory Animal Shared Resources, Roswell Park Cancer Institute, Buffalo, NY, USA.

Sandra Sexton (S)

Medical Oncology and Laboratory Animal Shared Resources, Roswell Park Cancer Institute, Buffalo, NY, USA.

Norbert Avril (N)

Department of Radiology, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.

Zheng-Rong Lu (ZR)

Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA.

Zhenghong Lee (Z)

Department of Radiology, Case Western Reserve University, Cleveland, OH, USA.

Classifications MeSH